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• Patient-derived organoids (PDOs) can be derived from malignant ascites and pleural effusions.
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Available online 4 April 2020Objective. Cancer patient-derived organoids (PDOs) grow as three dimensional (3D) structures in the pres-
ence of extracellular matrix and have been found to represent the original tumor's genetic complexity. In addi-
tion, PDOs can be grown and subjected to drug sensitivity testing in a shorter time course and with lesser
expense than patient-derived xenograftmodels. Many patients with recurrent ovarian cancer developmalignant
effusions that become refractory to chemotherapy. Since these same patients often present for palliative aspira-
tion of ascites or pleural effusions, there is a potential opportunity to obtain tumor specimens in the form ofmul-
ticellular spheroids (MCS) present in malignant effusion fluids. Our objective was to develop a short duration
culture of MCS from ovarian cancer malignant effusions in conditions selected to support organoid growth and
use them as a platform for empirical drug sensitivity testing.
Methods. In this study, malignant effusion specimens were collected from patients with high-grade serous
ovarian carcinoma (HGSOC). MCS were recovered and subjected to culture conditions designed to support
organoid growth. In a subset of specimens, RNA-sequencing was performed at two time points during the
short-term culture to determine changes in transcriptome in response to culture conditions. Organoid induction
was also characterized in these specimens using Ki67 staining and histologic analysis. Drug sensitivity testing
was performed on all specimens.
Results.Ourmodel describes organoids formedwithin days of primary culture,which can recapitulate the his-
tological features of malignant ascites fluid and can be expanded for at least 6 days. RNA-seq analysis of four pa-
tient specimens showed that within 6 days of culture, there was significant up-regulation of genes related to
cellular proliferation, epithelial-mesenchymal transition, and KRAS signaling pathways. Drug sensitivity testing
identified several agents with therapeutic potential.
Conclusions. Short duration organoid culture of MCS from HGSOC malignant effusions can be used as a plat-
form for empiric drug sensitivity testing. These ex vivomodels may be helpful in screening new or existing ther-
apeutic agents prior to individualized treatment options.
© 2020 Elsevier Inc. All rights reserved.Keywords:
Ovarian cancer
Patient-derived organoid models
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784 H. Chen et al. / Gynecologic Oncology 157 (2020) 783–7921. IntroductionOvarian cancer is the deadliest gynecologic cancer and often is asso-
ciated with malignant effusions of the abdomen or pleural space that
becomes refractory to treatment. High-grade serous carcinoma of the
ovary, fallopian tube and peritoneum is the predominant histology [1].
Second-line chemotherapy for platinum-resistant recurrent ovarian
cancer has objective response rates b30%, and the five-year mortality
rate between 70 and 90% has not changed significantly in the past ten
years [1,2]. Ovarian cancer genomic analysis reveals that extensive alle-
lic copy number changes rather than common driver mutations are
characteristic of the disease [3], making genomically-targeted treat-
ment more difficult. The lack of reliable and validated in vitro models
for empiric testing of potential drug sensitivities has also hindered prog-
ress. Two dimensional (2D) in vitro cultures have been used as ovarian
cancer models and more recently, patient-derived xenografts (PDX)
have been successfully developed [4]. A major disadvantage of 2D cul-
ture is that genetic heterogeneity found in the original tumors is poorly
represented [5]. PDX models, while maintaining genomic heterogene-
ity, are costly, time-consuming and not always successful. Some of
these disadvantages can be overcome by using PDO cultures. PDOs
grow as 3D structures within the extracellular matrix and may develop
from tumor-initiating cells that recapitulate the original tumor's genetic
complexity [6]. PDOs have been grown with a high success rate over a
short duration in serum-freemedia with defined supplements designed
to support the stem cell-like niche [7]. Accumulating evidence suggests
that this stem cell-like niche in malignant tumors is a repository of
treatment resistance and tumor recurrence, and consequently has
high clinical relevance [8–11]. Tumors from the colon, prostate, breast,
pancreas, endometrium and other solid tumors have been propagated
at a high rate of success using PDO techniques. The resulting PDOs
closely resemble the original patient tumor in morphology, mutation
profile and gene expression patterns [12–14]. PDOs provide a fast, effec-
tive model for use in functional assays of individual patient tumors, and
early clinical trials are underway to correlate drug sensitivity in PDO cul-
tures with response to targeted agents in patients with gastrointestinal
cancers [13,15]. Prominent genomic changes associatedwith HGSOC in-
clude allelic copy number changes and TP53mutations, as opposed to a
group of mutated driver genes associated with other cancer types. Ac-
cordingly, the general lack of oncogene mutations in HGSOC affords
few opportunities for molecularly targeted therapy. Empirical testing
of drugs using ex vivo organoid technologymay provide rapid screening
of active drugs in these patients.
Multicellular spheroids (MCS) are metastatic units that can adhere
to the mesothelium and invade the extracellular matrix to facilitate
peritoneal dissemination, and they could be considered the driving
force in tumor metastasis in ovarian cancer [16]. Consequently,
ex vivo models usingMCS that recapitulate the early stages of metasta-
sis could be valuable in testing experimental therapeutic agents. The
current study presents evidence that MCS from ovarian cancer malig-
nant effusions subjected to short duration culture under conditions
known to support organoid growth show proliferative characteristics,
EMT gene expression signature, KRAS pathway activation, and variable
response to experimental and conventional therapeutics. These ex vivo
models can beused as a platform for empiric drug sensitivity testing and
advancing treatment options for ovarian cancer.
2. Methods
2.1. Recovery of MCS from ovarian cancer effusions
High-grade serous ovarian cancer specimens from ascites or pleural
effusion fluid were collected for the study. Only effusion fluids not
needed for pathologic diagnosis and considered “leftover” were col-
lected. Specimens were provided by the UC Davis Pathology
Biorepository which is jointly funded by the UC Davis ComprehensiveCancer Center Support Grant (CCSG) awarded by the National Cancer
Institute and the Department of Pathology at UC Davis. The study was
approved through the UC Davis Institutional Review Board. All samples
were coded with a study number and all personal health information
was removed. Patient demographics, tumor characteristics, and clinical
information were provided in a de-identified manner. Effusion fluids
were centrifuged (365 ×g, 15 min) and cell pellets were resuspended
in Dulbecco's Phosphate Buffered Saline (DPBS, Gibco #14040-133).
Cold ammonium chloride solution (Stemcell Technologies #07800)
was added in a 4:1 dilution for red blood cell lysis. After 10 min on ice,
the cells were centrifuged and resuspended in DPBS. The specimen
was then passed through a 100-μm sieve to remove large aggregates
and debris. The flow-through was passed through a 38-μm sieve to re-
move most mononuclear cells. MCS structures between 38- to 100-μm
were recovered by backflushing, washed and cryopreserved (mFreSR,
Stemcell Technologies #05855).
2.2. Initial culture of MCS and organoid formation
For initial organoid culture, previously cryopreserved 38–100 μm
MCS were rapidly thawed, washed with cold DMEM/F12 (Gibco
#11320-033) and resuspended in cold Cultrex®ReducedGrowth Factor
Basement Membrane Extract, Type 2 (BME) (F # 343301001). MCS
were then deposited in 10 μL droplets in 6-well tissue culture plates. Ap-
proximately 0.05–0.1 mL of packed MCS material was used per 6-well
tissue culture plate. A test droplet (10 μL) droplet was plated and visu-
alized under the microscope. MCS were counted and we aimed to
have approximately 100 per droplet. Material was resuspended if not
in this range. The droplets were allowed to solidify for 20 min at
37 °C. Each well was filled with 2 mL “complete medium” (CM, similar
to that described by Sachs et al. [7] with some modifications), as fol-
lows: DMEM/F12, 10% R-spondin1 conditioned medium, 2% B27 sup-
plement (Gibco #17504-044), 10 mM HEPES (Gibco #15630080), 1%
Glutamax (Gibco #35050), 1.25 mM N-acetyl cysteine (Sigma
#S7250), 100 μg/mL Primocin (InvivoGen #ant-pm), 1% Antibiotic-
Antimycotic (Gibco #15240-062), 1mM nicotinamide (Sigma
#N0636), 0.5 μM A 83–01 (Sigma #SML0788), 5 nM Neuregulin 1
(Abcam #ab73753), 5 ng/mL FGF-7 (Peprotech #10019), 20 ng/mL
FGF-10 (PeproTech #10026), 100 ng/mL Noggin (PeproTech
#12010C), 5 ng/mL EGF (Gibco #PHG0314), 0.5 μM SB 202190 (Sigma
#S70767), and 5 μM Y-27632 (Stemcell technologies #72304). For
RSPO1 conditioned medium, the recombinant cell line HA-R-Spondin-
Fc 293T was purchased from Trevigen (#3710-001-01) and serum-
free conditioned CD 293 medium (Gibco #11913-019) was produced
as described by the supplier's instructions. The cultures were placed at
37 °C with 5% CO2.
2.3. Short-term organoid growth assay
Following initial culture of MCS in BME droplets, the developing
organoids were recovered after 3–4 days of culture using Cell Recovery
Reagent (Corning #354253), washed in cold DMEM/F12, suspended in
CM+2% BME and distributed, 50 μL per well containing approximately
100 organoids/well, into 96-well plates (low evaporation lid, Sigma
#CLS3595), the wells of which had been previously coated with 15 μL
of 7.5 mg/mL BME [17].
For cytotoxicity assays using targeted drugs or experimental thera-
peutic agents, a single drug concentration was selected that was at or
near the pharmacokinetic maximum (Cmax) value associated with the
therapeutic dosage in humans from published clinical trials. When
pharmacokinetic data were not available, drugs were screened at a 1
micromolar concentration. Drugs tested and their sources are detailed
in Table 1. After 24 h of culture (on culture day 1), 25 μL of each drug so-
lution to be tested, dissolved in CM at 3 times the final target concentra-
tion, was added to each of 6 replicate wells. Except for carboplatin and
abraxane which were dissolved in aqueous solutions, all drugs were
Table 1
Inhibitors used in drug assay.
Drug Mechanism of action Published
Cmax
(μM)
Target
concentration
(μM)
Mocetinostat HDAC inhibitor 0.5 [39] 0.5
Trametinib MEK1/2 inhibitor 0.08 [40] 0.1
LY294002 PI3Kα/δ/β inhibitor 26 [41] 26
AZD5363 AKT 1/2/3 inhibitor 4.7 [42] 5
BBI503 Stemness kinase inhibitor – 2.5
MK-1775 Wee-1 inhibitor 2.66 [43] 3
Sorafenib Raf-1, B-Raf, VEGFR-2 inhibitor 12.5 [44] 12.5
APR-246 p53 re-activation/apoptosis
induction
250 [34] 200
CB5083 p97 inhibitor – 5
Napabucasin STAT3 inhibitor 1.5 [45] 1.5
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DMSO concentration of 0.1%. Cultures were incubated until day 6,
then assayed by CellTiter-Glo 3D Cell Viability Assay (Promega
#G9681) as described by Francies et al. [17]. Identical frozen aliquots
of 0.5 μM ATP solution (Pharmacia #27-2056-01), thawed and utilized
on each day of the CellTiter-Glo (CTG) assay, were used to normalize re-
sults for growth comparisons. These control wells were assayed on day
0 (to check viability), day 1 and day 6. Representative images of control
well organoids were obtained by video microscopy (Olympus IX81).
Mean organoid colony areas were measured using ImageJ 1.52a soft-
ware. For statistical comparison, the Student's t-test was utilized. Fold-
change in growth between day 1 and day 6was determined by compar-
ison of ATP-normalized CTG results for control wells. In samples per-
formed in duplicate or triplicate, control well CTG results were
averaged. For IC50 determination, 9 two-fold dilutions of each test
drug were tested and IC50 values calculated with GraphPad Prism soft-
ware (v8). Percent inhibition was calculated as follows: percent inhibi-
tion=100–100 (D / C), where C=average luminosity among 6 control
replicates, andD=average luminosity among6drug replicates. Percent
inhibition of b50% in the drug screen was considered “resistant”.
2.4. Characterization of organoid induction from MCS to day 6 organoids
Organoid induction was studied over 6 days of culture by video mi-
croscopy, formalin-fixed paraffin-embedded H&E stain, Ki67 index, and
RNA-Sequencing (RNA-seq) analysis. Uncultured day 0 MCS (thawed
and washed in DMEM) were compared to matched day 6 organoidsTable 2
Clinicodemographics of participants.
Participant Specimen Race/ethnicity Age Source
1
OV469 White/non-Hispanic 56 Ascites
2
OV778 White/non-Hispanic 74 Ascites
3b
OV798
OV817
OV820
OV838
OV840
White/non-Hispanic 61 Pleural effusion
4
OV899
OV860
White/non-Hispanic 74 Ascites
5
OV867 White/non-Hispanic 62 Ascites
OV875
OV882
Ascites
Ascites
6c
OV870 White/non-Hispanic 54 Ascites
OV888 Ascites
C = Cycle; HGS = High grade serous; HGSOC= High grade serous ovarian cancer.
a Stage at time of original diagnosis.
b Prior to first specimen, patient underwent treatment with AZD2014, bevacizumab, carbop
agent.
c Prior to first specimen, patient underwent treatment with ABT888 (PARP inhibitor), bevac
lection of OV888, patient initiated therapy with anastrazole.(recovered from BME droplet culture with Cell-Recovery solution)
from four unique subjects.MCS andorganoidswere placed under cover-
slips, stainedwith trypan blue and representative imageswere obtained
by video microscopy (Olympus IX81). Uncultured day 0 MCS and day 6
organoids were fixed and processed for histology and Ki67 staining as
previously described [12].
2.5. Transcriptome analysis of HGSOC multi-cellular spheroids with RNA-
sequencing (RNA-seq)
Day 0 MCS and Day 6 organoid samples were submitted to the UC
Davis Comprehensive Cancer Center's Genomics Shared Resource
(GSR) for isolation of total cellular RNA and RNA-seq analysis. Total cel-
lular RNAwas isolated from snap-frozen spheroids using the TRIzol Re-
agent (Invitrogen) and a modified protocol that incorporates an
additional extraction with phenol/chloroform/isoamyl alcohol
(25,24,1, pH 4.3), followed by an additional clean-up with an RNeasy
spin column (Qiagen). Stranded mRNA-seq libraries were prepared
from 100 ng total RNA using the NEBNext Ultra Directional RNA Library
Prep Kit (NewEngland BioLabs, Ipswich,MA) according to themanufac-
turer's standard protocol, and as previously described [18]. Subse-
quently, libraries were combined for multiplex sequencing on an
Illumina HiSeq 4000 System (2 × 150 bp, paired-end, ≥20 × 106 reads
per sample). A Salmon-tximport-DESeq2 workflow was utilized for pri-
mary and secondary analysis of the RNA-Seq data (FASTQ format). Se-
quence read mapping to the reference genome assembly (Dec. 2013,
GRCh38/hg38) and transcript abundance estimation were performed
with Salmon [19]. Transcript-level read counts were prepared with the
R package tximport [20], annotated with GENCODE Human Release 29
(GRCh38.p12), and differential gene expression analysis was conducted
with DESeq2 [21]. Principal component analysis (PCA), hierarchical
clustering, and heatmap visualization were performed with the Strand
NGS software package (Strand Life Sciences). Gene Set Enrichment
Analysis (GSEA) was performed using the predefined hallmark gene
set [22,23]. A ranked gene list was created. All values N1 were consid-
ered to have been upregulated in Day 6 vs Day 0 and all values b1,
downregulated.
3. Results
Table 2 shows the demographic characteristics of 6 unique subjects
from which 14 separate specimens were recovered for analysis. MCS
from malignant effusions were structurally heterogeneous with a wideStage/histologya Prior treatment Days from last infusion
IIIC HGS
Peritoneal cancer
Untreated NA
IVB HGSOC Untreated NA
IIIC HGSOC C1 paclitaxel/bevacizumab
C4 paclitaxel/bevacizumab
C5 paclitaxel/bevacizumab
C6 paclitaxel/bevacizumab
C1 gemcitabine
21
14
7
14
2
IIIC HGSOC Untreated
C1 carboplatin/paclitaxel
NA
4
IVB HGSOC C1 carboplatin/paclitaxel 3
C1 carboplatin/doxorubicin
C1 carboplatin/doxorubicin
IIIC HGSOC See footnote 46
latin, cisplatin, doxorubicin, olaparib, paclitaxel, topotecan, in combination or as a single
izumab, carboplatin, pegylated liposomal doxorubicin, paclitaxel, topotecan. Prior to col-
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specimen before and after sieving. The amount of MCS material recov-
ered (post sieving, 38–100 μm) per liter of malignant effusion varied
with an average of 0.55 mL packed MCS material per liter of effusion
(n = 14, range: 0.05–2.0). Seven additional specimens were collected
(not reported in Table 2), however in 4 cases, chemotherapy was ad-
ministered within 2 weeks of sampling. No material for further testing
was obtained. In 3 cases, scant material was obtained which was insuf-
ficient to perform complete testing.
Fig. 2 shows representative photomicrographs of paraformaldehyde-
fixed, paraffin-embedded material stained with hematoxylin/eosin
(H&E). Variable numbers of non-viable appearing cells were seen in
both MCS and day 6 specimens, but day 6 specimens showed larger
cell groupings with conspicuous mitotic figures. Comparing MCS to
day 6 organoids, Ki67 index increased on average by 3.5-fold. Individual
Ki67 indices for each of the 4 specimens are shown in Table S1. Day 6
organoids also showed evidence of cell death with more trypan blue-
stained cells in organoids recovered fromBMEdroplets, andmore eosin-
ophilic debris along with fragmented nuclei (data not shown).
Molecular characterization of the same four pairs of Day 0 (D0)MCS
and Day 6 (D6) organoids was conducted by RNA-Seq analysis.
Organoid induction (culture D6 vs. uncultured D0 MCS) for all four
specimens produced 1584 differentially-expressed genes (DEG; paired
t-test, p b 0.05), and hierarchical clustering of the 775 up-regulated
and 805 down-regulated genes resulted in organization of the D0 MCS
and D6 organoids into two distinct sub-trees (Fig. 3A). The gene expres-
sion changes suggested a shift to an actively proliferating population
(up-regulation of PCNA 1.7-fold and MKI67 3.3-fold), consistent with
theKi67 IHC. Also observed in all four specimenswas amoderate down-
regulation of differentiation markersMUC1 (1.7-fold) andMUC16 (2.4-
fold). Epithelial differentiation marker E-cadherin (CDH1) was slightly
down-regulated (1.4-fold). Among the most highly up-regulated
genes were several metalloproteinases involved in extracellular matrix
remodeling and cell adhesion (MMP9 61-fold, MMP1 25-fold, and
ADAMDEC1 31-fold) and a member of the P450 cytochrome oxidase
family CYP1A1 (60-fold). Quantitative RT-PCR (qRT-PCR) analysis indi-
cates MMP-9, MMP-1 and CYP1A are consistently upregulated upon
organoid induction (D6 vs D0) (Fig. 4). Among the most markedly
down-regulated genes were FOSB (108-fold) - a subunit of the AP-1
transcription factor; RGS1 (55-fold) - a regulator of G protein signaling;
andWNT11 (43-fold) - a secreted signaling factor (Fig. 3B). The qRT-PCR
analysis confirmed that RGS-1 and WNT11 are consistentlyFig. 1.Representative specimen before and after sieving (38–100 μm).Malignant effusion specim
solution was then sieved in order to recover 38–100 μmmaterial. Panel A represents heterogedownregulated upon organoid induction in these samples (Fig. 4). Ex-
cept for ABCG2 and EZH2, none of the genes purported to be associated
with cancer stemness potential (including CD44, CD133, ALDH1A1,
NOTCH1, and STAT5B) showed consistent up-regulation during organoid
induction in the four specimens examined. qRT-PCR showed upregula-
tion of EZH2 upon organoid induction in all four specimens (Fig. 4).
ABCG2 (an ATP-binding cassette transporter) was consistently up-
regulated, average 10.6-fold, among the four specimens but presented
as a very low abundance transcript in all specimens. CD44 was up-
regulated in 3 of 4 specimens (average 3.0-fold) and STAT5Bwas slightly
down-regulated in all four. GSEA indicated that organoid induction in
these four specimens was strongly associated with up-regulation in
Hallmark gene sets for epithelial-mesenchymal transition (p b 0.001),
KRAS signaling (p b 0.001), IL6/JAK/STAT pathway signaling (p =
0.003), and other pathways commonly up-regulated in malignant tis-
sues (e.g. MTORC signaling (p b 0.001) and E2F target signaling
(p b 0.001). There were no significantly downregulated gene sets in
this analysis. Fig. S1 illustrates these gene sets. These observations sug-
gest that organoids induced under these conditions show transcrip-
tional programs consistent with the proliferative phenotype.
The short-term drug sensitivity assay utilized organoids cultured for
3–4 days in BME droplets, recovered, then distributed in 96 well-plates
and cultured for an additional 6 days in the presence of drugs prior to
CTG assay. During this phase of the assay (between days 1 and 6 of
assay culture), growth was also demonstrated in the control wells.
Organoid areas consistently increased (from a Day 1 average of
3500μm2 to a Day 6 average of 6500μm2 for an increase of 1.87-fold,
n = 7). Fig. 5 depicts a representative appearance of day 1 and day 6
control well organoids. Fold increases in the ATP content (as measured
by CellTiter Glo assay, adjustedwith internal ATP standard) of untreated
control wells between day 1 and day 6 of the assay were less marked
(mean 1.035, n = 14, range (0.22–2.73). One value was excluded as
the fold growth was 5.76 which was deemed to be an extreme outlier.
Experimental therapeutic agents (some in clinical trials and some
still in the preclinical phase) were tested for activity in this organoid
platform using a single screening concentration. Table 3 shows the re-
sults of screening testing for 10 drugs in 10 specimens from 6 unique
subjects. Drugs that showed the most consistent activity (APR-246,
CB-5083, MK-1775, and Sorafenib) were further assayed for IC50 values
in duplicate or triplicate when there was sufficient material. IC50 assays
were performed without screening plates in 4 specimens in order to
conserve material. For these specimens, drugs were chosen based onenswere centrifuged, treatedwith cold ammonium chloride and suspended inDPBS. This
neous pre-sieved material and panel B represents post-sieved MCS (38–100 μm) (100×).
Fig. 2. Characterization of organoid byH&E (A–B) and Ki67 (C–D). A representsMCS (day 0)while B depicts organoids on day 6. Variable numbers of non-viable appearing cells were seen
in both MCS and day 6 specimens, but day 6 specimens showed larger cell groupings with frequently-seen mitotic figures (arrow). C represents Ki67 staining for MCS (day 0) while D
represents organoids on day 6. Ki67 index increased on average by 3.5-fold. A–B: 400×, C–D: 200×.
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Carboplatin was also subjected to IC50 measurement. Fig. S3 shows rep-
resentative triplicate IC50 curves. Table 4 shows IC50 values for a total of
118 assaysmostly done in triplicate, on 13 different specimens (derived
from6unique subjects)with 5 different drugs (carboplatin and4 exper-
imental therapeutic agents).
The pattern for taxane inhibition in this assay was complex. Five
specimens from 4 unique subjects were subjected to paclitaxel in IC50
assays. OV820 yielded an IC50 of 0.08 μM. IC50 assays in the remaining
specimens (n=4)withmaximumpaclitaxel concentration of 40 μMre-
sulted in resistance. Because of solubility issues with paclitaxel, a higher
concentration could not be achieved for testing. Nab-paclitaxel was
used to achieve higher concentrations in the assay. OV820 and OV838
(participant 3) showed an inflection in the viability curve at low nab-
paclitaxel concentrations (range of 0.01–0.26 μm). OV838 also showed
more inhibition with higher concentrations (range of 5.91–54.97 μM,
Fig. S2). Other specimens (OV870 and OV888) had a more traditional
one phase inhibition with the IC50 achieved at a high concentration
(range 20.8–51.7 μM). OV469 and OV899 were completely unaffected
by taxanes, even at the highest concentration. In all, 23 IC50 assays
were performed with taxanes (5 with paclitaxel and 18 with nab-
paclitaxel).
4. Discussion
Under the culture conditions used here, organoids developed from
MCS within days of initiating culture. Based on a detailed analysis of
four specimens, organoid inductionwas characterized by the following:
1) an increase in the mean area of organoid structures; 2) moreevidence of cell death; 3) increased cell proliferation; 4) an up-
regulation of genes related to cellular proliferation, epithelial-
mesenchymal transition, and KRAS signaling pathways. Organoid in-
duction under these conditions provides a model for the study of a
highly proliferative cell population derived from a subset of original
MCS, perhaps recapitulating the initiation of metastatic tumor growth
following implantation of MCS onto the peritoneal surface. Such a
model may be useful in empiric drug sensitivity testing.
This organoid inductionmodel was adapted for drug sensitivity test-
ing of 10 targeted agents aswell as carboplatin and taxanes. Drug sensi-
tivity results using a single targeted drug concentration on 10
specimens originating from 6 unique patients showed that four drugs
(APR-246, CB-5083, MK-1775, and Sorafenib) had the most consistent
inhibitory effects. These four targeted agents along with carboplatin,
paclitaxel and/or nab-paclitaxel were subjected to IC50 testing. IC50
values for APR-246, MK1775 and Sorafenib were close to or lower
than the published Cmax value associated with therapeutic dosage. Al-
though there was some consistency, response to drugs in the screening
assay was variable between subjects, highlighting the importance of an
empiric assay for each patient and the need for individualized therapy.
IC50 values for carboplatin (range 18.7–98.8 μM) were generally
lower than or approximately equal to published Cmax values. Although
contemporary carboplatin doses are expressed as AUC values, prior
pharmacokinetic studies [24] determined Cmax values for a range of
carboplatin doses. Carboplatin delivered at 300 and 450 mg/m2 yielded
Cmax values of 85 and 149 μM, respectively. IC50 values for carboplatin
in the organoid assay described here (Table 4 and Supplemental Fig. S3)
weremostly below these Cmax values suggesting that organoid viability
should be substantially affected by the concentrations of carboplatin
Fig. 3.Molecular characterization of organoid culture. A: Hierarchical clustering and heatmap of 1584 statistically significant differentially-expressed genes (DEG) in day 6 organoids
compared to MCS (day 0); p b 0.05, N1× fold change. B: Fifty most highly DEGs (25 increased and decreased) in OVCA organoids after 6 days in organoid culture (MCS vs. day 6, paired
t-test, p b 0.05). Expression changes are depicted as red or blue bars, respectively.
788 H. Chen et al. / Gynecologic Oncology 157 (2020) 783–792that can be achieved in vivo with standard dosing. The maximum con-
centration used in the assay described here was 314 μM. Therefore,
had there been another inflection point approaching the published
Cmax, it likely would have been detected. IC50 values for carboplatin
suggests that this testing platform is probably not useful for determin-
ing clinically significant platinum sensitivity.
Paclitaxel was tested to a maximum of 40 μM showing that the IC50
was above this level (except for specimen OV820), however, solubility
issues prevented testing higher concentrations. Consequently, nab-
paclitaxel in aqueous solution was also tested and resulted in variable
responses. Specimens from one unique subject (participant1)were par-
ticularly sensitive to taxanes and two inflection points were noted; one
at a very low concentration and a second at a high concentration (Sup-
plemental Fig. S2). In other specimens, IC50 valuewas achieved at a con-
centration above the published Cmax while still others were entirely
resistant. This is consistent with the literature which suggests an ap-
proximately 20% response rate to single-agent Taxol in recurrent ovar-
ian cancer [25,26] and with Jabs et al. who noted that paclitaxel
resulted in inhibition in two out of nine patient cancer organoids [27].
It is interesting to note that among the experimental therapeutics,
Wee1 inhibitor MK-1775 (AZD1775) and VCP (p97) inhibitor CB-5083
show consistent growth inhibitor effects in low micromolar range in
all PDO models tested. Wee1 kinase regulates G2 checkpoint, and
tumor cells withmutations in TP53 are susceptible to G2 checkpoint ab-
rogation. Therefore, it is not surprising that PDO derived from HGSOC
characterized by mutations in TP53 show sensitivity to MK-1775. Al-
though overall survival data is immature, a recent phase II randomized
clinical trial of MK-1775 (NCT0137161) shows a significant increase in
the progression-free survival when MK-1775 was added to the
carboplatin-paclitaxel combination therapy compared to the doublet
[28]. Valosin-containing protein (VCP, also known as p97) is an AAA-
ATPase with diverse functions in protein and organelle homeostasis. Arecent genome-wide shRNA screen identifies VCP as a potential drug
target in ovarian cancer because VCP knockdown causes lineage-
specific dependencies in ovarian cancer [29]. A recently developed
p97 inhibitor CB-5083 shows a broad spectrum of cytotoxicity in over
300 cancer cell lines as well as antitumor activities in several cancer
cell line xenografts and patient-derived xenografts [30]. CB-5083 and
other VCP inhibitors show cytotoxicity against established ovarian can-
cer cell lines in 2D culture [31]. Finally, it is important to note that some
PDOs (OV798 and OV840) show enhanced sensitivity to APR-246,
which reactivates specific p53 mutants [32,33]. Interestingly, four
other PDOs (OV778, OV820, OV870, and OV899) are less sensitive to
APR-246. It is not surprising that OV820 and OV870 are less sensitive
to ARP-246 because they have truncationmutations (Fig. S4).Moreover,
OV778 andOV899harbormissensemutations (Fig. S4) but they are also
less sensitive to APR-246. These results suggest that somemissensemu-
tants are not amenable to rescue by APR-246, and cells harboring these
mutations are relatively insensitive to APR-246. Nonetheless, the IC50
for APR-246 in these models are in the high micromolar range that is
clinically achievable based on the Cmax values obtained from clinical
trials. Therefore, APR-246 may exert cytotoxic activity through addi-
tional targets, such as thioredoxin reductase [34,35]. Collectively,
these experimental therapeutic agents hold promise for further evalua-
tion of their clinical activities in patients with HGSOC.
The short-term organoid culture platform described here has limita-
tions. Cellularmaterial frompalliative aspiration of refractorymalignant
effusions is a non-renewable resource, although additional material can
sometimes be obtained if palliative aspiration is repeated. Some malig-
nant effusions contain insufficient cellular material for detailed study.
The assay employs a subpopulation of MCS structures separated by se-
lective sieving; larger or smaller structures could theoretically display
different results. Sieving to remove mononuclear cells may remove
tumor-associated fibroblasts or immune cells important in the tumor
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Fig. 4. qRT-PCR analysis of candidate gene expression affected upon organoid induction. To validate the RNA-seq data, we performed quantitative RT-PCR assay on selected genes.
Consistent with our RNA-seq data we observed a significant upregulation of genes MMP-9, MMP-1, CYP1A and EZH2 in the day 6 organoids in all samples in comparison to Day 0
(panels a, b, c and f). Similarly, significant downregulation observed in genes WNT-11 and RGS-1 were also consistent with our RNA seq data (panels d and e). These results indicate
that genes that are significantly up-regulated and downregulated between the two groups of our organoid cultures can be validated and confirmed through q-RT-PCR analysis,
respectively. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
Fig. 5. Organoid growth in drug assay. Organoid growth was studied via a number of methods. Representative appearance of OV820 Day 1 (A; 400×) and Day 6 (B; 400×) control well
organoids in the drug assay are depicted here. Organoids appeared larger on day 6.
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Table 3
Drug screening assays.
Agent % inhibition (log p value)
OV469 OV778 OV798a OV817a OV820a OV840a OV899b OV860b OV867 OV870
Olaparib
40.39
(−2.82)
56.46
(−1.73)
34.49
(−1.53)
20.72
(−4.67)
18.65
(−3.11)
31.10
(−1.58)
36.24
(−1.78)
22.00
(−1.62)
30.25
(−2.72)
18.4
(−3.15)
Paclitaxel 46.29
(−1.84)
17.69
(−0.39)
66.95
(−2.83)
61.61
(−6.38)
62.39
(−5.09)
81.89
(−4.35)
0.28
(−0.02)
22.95
(−1.33)
29.88
(−1.99)
21.91
(−2.59)
Mocetinostat
46.01
(−1.85)
−45.02
(−1.09)
41.4
(−1.22)
20.84
(−3.39)
92.84
(−6.35)
66.31
(−2.88)
36.89
(−2.75)
51.05
(−3.32)
3.57
(−0.45)
12.39
(−3.35)
Trametinib
37.81
(−2.74)
−91.96
(−1.70)
−66.94
(−2.53)
9.18
(−1.07)
44.87
(−3.64)
−18.14
(−0.68)
19.31
(−0.52)
17.06
(−1.82)
−39.75
(−1.61)
10.34
(−1.81)
LY294002
50.53
(−2.90)
−84.45
(−2.46)
74.93
(−2.14)
61.12
(−6.28)
78.77
(−5.50)
77.77
(−3.59)
−7.86
(−0.65)
28.48
(−1.89)
28.69
(−1.44)
0.37
(−0.4)
AZD5363
79.70
(−3.88)
−90.78
(−3.35)
58.90
(−1.78)
38.65
(−4.65)
80.16
(−5.21)
69.81
(−3.53)
24.57
(−1.37)
39.56
(−2.20)
39.63
(−2.79)
29.30
(−3.67)
BBI503
40.28
(−1.26)
−94.71
(−1.43)
−8.59
(−0.14) –
30.46
(−2.46)
−98.36
(−2.67)
37.60
(−2.66)
7.19
(−0.21)
8.69
(−0.67)
4.68
(−1.07)
MK-1775
80.59
(−3.81)
3.57
(−0.07)
90.32
(−2.42)
94.77
(−7.00)
98.21
(−5.78)
91.43
(−4.18)
65.79
(−4.29)
57.97
(−3.75)
63.51
(−3.90)
75.15
(−6.19)
Sorafenib
85.34
(−4.31)
33.00
(−1.16)
−32.89
(−0.62)
99.11
(−7.21)
97.71
(−5.78)
−10.31
(−0.30)
99.89
(−5.16)
17.32
(−1.01)
3.95
(−0.20)
98.99
(−6.84)
APR-246
99.98
(−4.54)
99.78
(−3.65)
99.96
(−2.74)
99.98
(−7.21)
99.99
(−5.84)
99.96
(−4.26)
98.2
(−6.35)
99.9
(−5.14)
99.90
(−4.70)
99.98
(−6.82)
CB-5083
99.97
(−4.54)
99.38
(−3.66)
99.94
(−2.74)
99.98
(−7.21)
99.96
(−5.85)
99.91
(−4.27)
95.39
(−5.86)
92.57
(−5.04)
97.95
(−4.61)
99.79
(−6.83)
Napabucasin
93.29
(−4.22)
−60.6
(−1.02)
0.73
(−0.01)
30.34
(−4.39)
13.02
(−1.90)
−99.69
(−1.85)
14.06
(−1.44)
75.78
(−3.86)
65.93
(−3.67)
25.80
(−4.44)
Results are reported as % inhibition (log p value).
Clinically significant inhibition defined as N50% inhibition, displayed in bold.
a Subject 3.
b Subject 4.
790 H. Chen et al. / Gynecologic Oncology 157 (2020) 783–792microenvironment. However, mononuclear cells in the malignant effu-
sions analyzed here usually represented more than half of the total cel-
lular material. Consequently, to assess tumor cells' response to
treatment, the mononuclear cell fraction was excluded in these
experiments.
Repeated measurement of IC50 values for some drugs tested here
showed variability. Potential sources of variability include different via-
bility of cryopreserved aliquots of the same specimen, variabilityTable 4
IC50 results.
Subject Specimen Carboplatin APR-246
1
OV469 16.22 [2] –
2
OV778
34.1
(18.7–44.5) [3]
31.75
(23.6–39.9) [
3
OV798 – 5.8 [1]
3
OV820
36.9
(28.7–38.3) [3]
38.2
(15.8–77.8) [
3
OV838
38.4
(34.8–41.4) [3]
94.2
(85.5–130.5)
3
OV840 – 7.4 [1]
4
OV899
39.4
(28.0–54.5) [3]
47.9
(31.9–57) [3]
4
OV860
47.1
(42.2–55.9) [3]
22.2
(16.5–27.9) [
5
OV867
65.4
(45.3–98.8) [3]
18.0
(7–38.8) [3]
5
OV875 41.3 [1] 29.1 [1]
5
OV882
49.9
(19.7–70.6) [3]
62.88
(31.1–90.9) [
6
OV870
65.6
(50.3–87.2) [3]
92.23
(34.3–148.3)
6
OV888
75.3
(61.9–94.2) [3]
126.3
(99.6–140.6)
Results are displayed as IC50 (μM) (range) [n].induced by exposure to chemotherapy soon before specimen acquisi-
tion and variability of the distribution of organoids into each assay
well. In situ methods for measuring the proportion of living vs. dead
cells inside each organoid could increase the accuracy of this platform
[27]. The medium described by Sachs et al. was selected since genomic
analysis has established that at least one subtype of breast cancer shares
the features of high copy number changes and TP53 mutations that
characterize HGSOC [7,36]. Hill et al. recently reported the results ofCB-5083 MK-1775 Sorafenib
– – –
2]
1.35
(0.5–2.2) [2]
– –
1.0 [1] 0.2 [1] N12.5 [1]
3]
1.17
(0.6–1.5) [3]
0.6
(0.2–1.1) [3]
2.7
[1]
[2]
1.18
(0.9–1.4) [3]
1.4
(0.9–2.2) [3]
–
0.6 [1] 0.4 [1] N12.5 [1]
0.5
(0.4–0.5) [3]
0.8
(0.8–0.8) [2]
1.8
(1.8–5.7) [2]
2]
0.4
(0.4–0.4) [2]
1.1 [1] –
1.8
(0.8–2.4) [3]
1.2 [1] –
1.3 [1] – –
3]
1.4
(1–1.9) [3]
0.5
(0.3–0.8) [3]
2.8 [1]
[3]
1.5
(0.8–2.9) [3]
0.2
(0.1–0.4) [3]
3.5
(3.2–4.8) [3]
[3]
1.2
(0.5–1.9) [3]
0.3
(0.1–0.5) [3]
1.6
(1.2–2.0) [3]
791H. Chen et al. / Gynecologic Oncology 157 (2020) 783–792short-term ovarian cancer PDO cultures showing the potential value of
organoid culture in assessing targetable defects, particularly those
with DNA repair defects [37].
Though primary tumors can be removed surgically, metastatic tu-
mors usually require drug therapy. Malignant effusion represents a
form of metastatic disease that often becomes refractory to drug treat-
ment. Palliative removal of recurrent effusions is a common and tempo-
rarily effectivemeans of reducing symptomsof these conditions but also
allows for access to individual patient's tumor cells for empirical testing.
The drug testing platform described here is feasible with this group of
patients. Though the development of long-term organoid lines that
can be continuously passaged and manipulated experimentally has
many advantages, the time it takes to establish each line may preclude
real-time clinical application for individual patients. Also, there is the
possibility that genetic drift or subclone selection may occur during
long-term culture such that the resulting organoid line is less represen-
tative of the original tumor. Short-term culture has the advantage of
allowing for drug testing within one week of specimen acquisition,
and though limited by the quantity of cellular material initially ob-
tained, it opens the possibility of empirical testing of potential therapeu-
tic agents in a time frame that could affect clinical outcomes. Because of
the complexities of ovarian cancer genomic changes, the assay approach
described here was developed to allow empirical testing of drugs that
might not be considered as options for salvage therapy.
An important question for any study using PDOs is to relate the ob-
servations to clinical results. The goal of the present study was not to
correlate clinical outcomes to assay results, however based on limited
de-identified clinical information available, all patients did progress or
recur after first line therapy (platinum and taxane). Interestingly, the
majority of unique subjects PDOs were also resistant to taxane at stan-
dard doses. Two specimens (OV899 and OV778) are from participants
who had not yet received chemotherapy at the time of effusion collec-
tion. These patients both progressed on platinum/taxane therapy and
PDOs from both specimens were resistant to taxane. In the literature,
initial reports comparing organoid drug sensitivity assay results and
clinical outcomes are beginning to accumulate. Sachs et al. demon-
strated that PDOs from breast cancer had responses to treatment that
matched the patient's outcomes [7]. Currently, the TUMOROID and
SENSOR trials are using PDOs to allocate patients for treatment with
targeted agents based on PDO drug sensitivities [38]. Similar clinical tri-
als for HGSOC can be helpful in determining effective and personalized
treatment for patients.
Finally, these PDOs may also be useful for dissecting the molecular
mechanisms associated with treatment resistance. PDOs grown under
3D condition can be selected with chemotherapy in parallel to patient
receiving treatment. Resistant cells that persist and expand after
ex vivo drug exposure can be re-evaluated for genetic alterations to
help explain ex vivo resistant mechanisms. In parallel, corresponding
recurrent patient samples can be re-evaluated for genetic alterations
and compared with genetic alterations identified from ex vivo selected
PDOs. These comparative studiesmay provide newmechanistic insights
into clinically relevant drug resistance mechanisms.5. Conclusions
PDO cultures were successfully grown from MCS present in HGSOC
in serum-free conditions. A short-duration PDO culture can be used to
study drug susceptibilities for individual tumors. PDO-based in vitro
drug sensitivity testing of MCS from ovarian cancer malignant effusions
can provide quick information regarding targeted treatments that may
be beneficial for a group of patients who often exhaust standard thera-
peutic options. Future clinical studies will be needed to correlate PDO
assay results with patient outcomes.
Supplementary data to this article can be found online at https://doi.
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